GL Pharm Tech Corp. (KOSDAQ: 204840)
South Korea flag South Korea · Delayed Price · Currency is KRW
1,131.00
-16.00 (-1.39%)
Oct 11, 2024, 9:00 AM KST

GL Pharm Tech Company Description

GL Pharm Tech Corp. provides generic drugs and incrementally modified drug (IMD) formulation technology to pharmaceutical companies in South Korea.

The company offers IMD for gastritis, antidepressant, anorectic, and antibiotic indications. It also provides generic drugs for cardiovascular, urology, pain, anti-infection, gastric disease, diabetes, central nervous system disease, respiratory disease, transplantation, and other areas.

In addition, the company engages in developing new molecule entity pipeline products for dry eye disease.

Further, it provides Cabalin CR extended-release tablet and Jample Ibufen syrup for the nervous system and sensory organs; Gisoren tablets for individual organs, digestive system, and peptic ulcer drugs; and Genstring Troki for treating individual organs and digestive system, as well as oral use.

GL Pharm Tech Corp. was founded in 2002 and is headquartered in Seongnam-si, South Korea.

GL Pharm Tech Corp.
Country South Korea
Founded 2002
Industry Pharmaceutical Preparations
Employees 29
CEO Hun-Sik Wang

Contact Details

Address:
714, Jungang Indussia 5
Seongnam-si
South Korea
Phone 82 3 1739 5220
Website glpt.co.kr

Stock Details

Ticker Symbol 204840
Exchange KOSDAQ
Fiscal Year January - December
Reporting Currency KRW
SIC Code 2834

Key Executives

Name Position
Hun-Sik Wang Chief Executive Officer